ClinicalTrials.gg
RecruitingNCT05288179Updated Nov 24, 2025

Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis

A Phase 3 interventional study of Pirfenidone Capsules and placebo capsules in Pneumoconiosis, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study is a randomized, double-blind, placebo-controlled, multicenter clinical study.

The main purpose of this study was to confirm the efficacy and safety of pirfenidone capsules in the treatment of pneumoconiosis.

Read the detailed description

272 patients with pneumoconiosis participated in the 52-week study and were randomized to pirfenidone or placebo.

02

Conditions studied

  • Pneumoconiosis
03

In context

Lead sponsor

Beijing Continent Pharmaceutical Co, Ltd. is the lead sponsor of 26 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age 18\~70 years old (including 18 years old and 70 years old), gender is not limited.

    2. Diagnosed with silicosis or coal worker's pneumoconiosis, in line with GBZ 70-2015 "Diagnosis of Occupational Pneumoconiosis".

    3. Forced vital capacity at screening percentage of predicted value %FVC≥40% and \<80% 4. The percentage of carbon monoxide dispersion in the predicted value at the time of screening %DLCO≥30% and \<80%.

    5.HRCT at screening showed diffuse interstitial changes in the lungs. 6. Patients voluntarily participated in this trial, with good compliance, and had the ability to understand and sign before the study.

Exclusion criteria

Exclusion Criteria:

  • 1. Those who do not meet any of the inclusion criteria. 2. Those who have received lung lavage therapy within 3 months and plan to receive lung lavage therapy during the trial.

    3. or AST > 3 times . 4. TBiL > 2 times ULN. 5. \<30 mL/min. 6. Patients with co-infection or high fever within 4 weeks prior to screening, including but not limited to acute bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis.

    7. Combined with tuberculosis or lung cancer. 8. Significant pulmonary arterial hypertension requiring parenteral therapy with epoprostenol/treprostinil or severe right heart failure determined by the investigator to be unsuitable to participate in the trial.

    9. Severe cardiovascular disease with one of the following conditions:

    1. Severe hypertension within 6 weeks and uncontrolled with treatment (≥160/100 mmHg);
    2. Myocardial infarction within 6 months;
    3. Unstable angina within 6 months. 10. Coagulation parameters: (INR) > 2, prothrombin time (PT) prolongation > 1.5 times ULN.

      11. Other conditions or comorbidities that may interfere with testing procedures (eg, intolerance to interruption of supplemental oxygen during pulmonary function tests) or, based on the investigator's judgment, that may interfere with trial participation or that may put patients at risk.

      12. Patients with dysphagia or clinical signs of malabsorption or who require parenteral nutrition.

      13. With active peptic ulcer. 14. History of thrombotic events (including stroke and ) within 12 months.

      15. Use of cytotoxic drugs, drugs, cytokine-modulating drugs, or receptor antagonist drugs such as azathioprine, cyclophosphamide, cyclosporine, etanercept, infliximab, white Triene antagonists, methotrexate, tacrolimus, TNF-α inhibitors and tyrosine kinase inhibitors TKIs and other drugs.

      16. Use of interferon, bisbenzylisoquinoline alkaloids (tetrandrine), polyethylene pyrimidine nitroxide (gramsilpine), quinape phosphate, hydroxyquinoline phosphate, aluminum citrate within 1 month before randomization , nintedanib, or high-dose acetylcysteine.

      17. Patients who have previously used drugs that may cause pulmonary fibrosis, such as amiodarone, or have been exposed to asbestos, beryllium and other substances, or exposed to radioactive environments.

      18. to the drug or its components (eg, lactose).

      19. Investigator judges that due to other medical conditions is \< 2.5 years.

      20. Major surgery planned during treatment. 21. Women who were pregnant, breastfeeding, or planning to become pregnant during the trial.

      22. Women of childbearing age who are unwilling or unable to use a highly effective method of during the 28 days before or 3 months after dosing.

      23. According to the researcher, the patient is either alcohol or drug abuser. 24. mentally ill. 25. Those who participated in clinical trials of other drugs within 3 months. 26. Investigators judged to be unfit to participate in the trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
272 participants (estimated)

Study arms

  • Experimental
    Pirfenidone group

    Patient takes pirfenidone 3 times a day,Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time

    Drug: Pirfenidone Capsules

  • Placebo comparator
    placebo group

    Patients take a placebo 3 times a day,Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time

    Drug: placebo capsules

Interventions

  • After randomization, the experimental group took pirfenidone capsules 3 times a day,Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time

    Also known as: F647

  • Drugplacebo capsules

    After randomization, the experimental group took placebo capsules 3 times a day,Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time

    Also known as: N

06

What researchers measure

Primary outcomes

  1. Changes in pulmonary function FVC%

    Change in FVC % (FVC % predicted) at 52 weeks of treatment

    Time frame: 52 weeks

Secondary outcomes

  1. Pulmonary function FVC

    Changes in FVC (L) at 52 weeks of treatment

    Time frame: 52 weeks

  2. Changes in lung function DLco%

    Change in DLco% at 52 weeks of treatment

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Sep 2026, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Mar 21, 2022
StartActual
Jun 7, 2022
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05288179
Responsible party
Sponsor
First posted
Mar 21, 2022
Start date
Jun 7, 2022
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

Ling Zhang, Dr
Contact
zhangling@bjcontinent.com
13501209210 ext. +86
Huaping Dai, Dr
principal investigator · China-Japan Friendship Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion